We investigated the effect of 5-hydroxytryptamine 3A and 3B receptor (HTR3A and HTR3B) gene polymorphisms on nausea induced by paroxetine in Japanese psychiatric patients. Blood samples were collected from 78 individuals after at least 2 weeks treatment with the same daily dose of paroxetine. The patients visited every 2 weeks and the paroxetine dose was changed in response to their clinical symptoms. Nausea was assessed at each visit. The Tyr129Ser polymorphism of the HTR3B gene had a significant effect on the incidence of nausea (P ¼ 0.038). Logistic regression analysis also showed that patients with the Tyr/Tyr genotype had a 3.95-fold (P ¼ 0.048) higher risk of developing nausea than patients with the Ser allele. HTR3A gene polymorphisms and the CYP2D6 gene polymorphisms had no significant effect on the incidence of nausea. The mean score of nausea severity was corrected by the Bonferroni test. HTR3B gene polymorphisms are significant predictors of paroxetine-induced nausea.
Introduction
Nausea is a severe side effect induced by selective serotonin reuptake inhibitors (SSRIs). In general, SSRIs are better tolerated than tricyclic antidepressants, although gastrointestinal side effects can have an incidence of up to 40%, which can be severe enough to lead to early treatment discontinuation. 1, 2 Recently, 5-hydroxytryptamine 3 receptors (HTR3) have been considered to have an important role in SSRI-induced gastrointestinal side effects, since HTR3 antagonists cisapride and ondansetron were reported to reduce SSRI-induced gastrointestinal side effects. 3 HTR3 is a ligand-gated ion channel that mediates fast synaptic neurotransmission. 4 Central and peripheral HTR3 have different structures and different properties. 5 HTR3 exist in the area called the chemoreceptor trigger zone of the medulla oblongata, and are thought to be involved with the vomiting reflex. 6 HTR3 are also distributed in the autonomic, enteric and sensory nervous systems. 7 They also regulate the control pain sensation, movement of the digestive tract and vomiting by prompting nerve depolarization. 8 In particular, modification of HTR3 on the small intestinal mucosa is one of the mechanisms for regulation of antineoplastic-induced nausea and vomiting. 9 We do not have any data about the binding affinity of paroxetine for the 5-HT3 receptors. However, HTR3 antagonists such as cisapride and ondansetron were used for the therapy of nausea induced by SSRIs, and SSRIs such as fluvoxamine display a relatively high affinity for HTR2A. Thus, we considered that there might be some relationship between nausea induced by SSRIs such as paroxetine and the function of HTR3.
Murphy et al. 10 report that the T102C polymorphism of the HTR2A gene may predict the treatment discontinuation caused by paroxetine-induced side effects in older patients with depression. HTR3A and 3B genes have been assigned to chromosome 11q23.1-q23.3, 11 and several genetic variations have been reported. Tremblay et al. 12 report that variations in the HTR3B gene predict the efficacy of antiemetic treatment in cancer patients. However, no previous studies have investigated the effects of HTR3A and 3B gene polymorphisms on the occurrence of SSRIinduced nausea.
Cytochrome P450 (CYP) 2D6 has been shown to be involved in the metabolism of paroxetine, and CYP2D6 is known to have genetic polymorphisms that affect enzyme activity. 13 These observations suggest that the CYP2D6 gene polymorphism may be a predictor for paroxetine-induced side effects. On the other hand, Gerstenberg et al.
14 showed that steady-state plasma concentrations of fluvoxamine are not associated with incidence of nausea, and that CYP2D6 genotype does not affect nausea development. Therefore, further studies are needed to clarify whether CYP2D6 gene polymorphisms affect SSRI-induced side effects.
In this study, we investigated the effects of pharmacodynamic factors, such as HTR3A and 3B gene polymorphisms, and the effects of pharmacokinetic factors, such as CYP2D6 genotype, on the occurrence of paroxetine-induced nausea in Japanese psychiatric patients.
Materials and methods

Subjects
This study was conducted at Niigata University Medical Hospital, Japan, and the study protocol was approved by the Hospital Ethics Committee. Each subject provided written informed consent before enrolment. The subjects comprised 78 Japanese psychiatric outpatients (28 males, 50 females) aged 38.4713.8 years (mean7s.d., range 18-70 years.). Thirty-nine subjects had major depressive disorder, 25 had anxiety disorders, six had adjustment disorder, seven had a depressive disorder not otherwise specified, and one had other mood disorders. All patients were diagnosed according to DSM-IV-TR. The exclusion criteria were additional diagnoses of Axis I or II of DSM-IV-TR. Demographic data, medical history and laboratory data, including hematology, serology, electrolytes and urine analysis, were collected for each patient. Patients with obvious physical illnesses were excluded from the study. All patients were orally treated with paroxetine for their psychiatric illness. No patients were being treated with antiemetic medication during our study.
Study design
The patients visited the hospital every 2 weeks and side effects, including nausea, were assessed at each visit. The paroxetine dose was increased from 10 or 20 to 30 and 40 mg/day in response to clinical symptoms. We rated the side effects during the last 2 weeks and evaluated the severity of nausea according to our original scale, which included five graded items: 0, no nausea; 1, mild nausea for less than during the last 2 weeks; 2, mild nausea for more than 1 week during the last 2 weeks; 3, continuous, moderate nausea during the last 2 weeks; 4, continuous, severe nausea and vomiting during the last 2 weeks. Subjects with a score of 0 or 1 were defined as subjects without nausea, and those with a score or 2, 3 or 4 were defined as having nausea. The side effect raters were blind to the patients' genotypes.
Blood sampling
Blood sampling was performed using a Venoject s tube containing EDTA-Na (Terumo Japan, Tokyo, Japan) at week 1 for genotype detection and subsequently at the first appearance of nausea to measure the concentration of paroxetine. Blood samples were taken at 12 h after the final ingestion of paroxetine. Venous blood, 7 ml, were collected, and genomic DNA was extracted from the peripheral leukocytes by utilizing a QIAamp Blood Kit (QIAGEN, Valencia, CA, USA) within 2 h of collection.
Genotyping and determination of plasma concentration
Polymerase chain reaction (PCR) was used to determine the C195T and Pro16Ser genotypes of HTR3A gene according to the method of Niesler et al. 15 and the Tyr129Ser genotype of HTR3B gene according to the method of Tremblay et al.
12
CYP2D6*10 alleles causing decreased enzyme activity were identified by the C188T mutation using a two-step PCR as described by Johansson et al. 16 A long-PCR analysis was used to detect the *5 allele causing a lack of enzyme activity as described by Steen et al.
17
The plasma concentration of paroxetine was measured using column-switching high-performance liquid chromatography (HPLC) with ultraviolet detection. Paroxetine was extracted from plasma, to which cisapride had been added as an internal standard, with hexane-chloroform, and the extract was subjected to automated column-switching HPLC using a TSK BSA-C8 precolumn (Tosoh, Tokyo, Japan) for sample clean-up, and a TSK gel ODS-80TS column (Tosoh) for separation.
Statistical analysis
Statistical analysis was performed using SPSSII for Windows. Genotype and allele distributions were analyzed by the w 2 test. The clinical and demographic characteristics, sex, age, daily dose and paroxetine concentration were compared among groups by the unpaired t-test. The mean score of nausea severity was compared among each genotype group by one-way analysis of variance, and post hoc analysis of the mean score of nausea severity was carried out by using Bonferroni's test. Logistic regression analysis was used to compare the probability of the incidence of nausea. The level of significance was set at Po0.05.
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Results
The genotype frequencies of the HTR3A, HTR3B and CYP2D6 genes are shown in Tables 1-3. All of these genetic variations were in Hardy-Weinberg equilibrium. HTR3A C195T polymorphism genotype was not detected in four patients. There were no differences in nausea between each diagnostic groups (e.g. major depressive disorders and anxiety disorders (P ¼ 0.12)). Therefore, we consider that the nausea observed in the present study was induced only by paroxetine. There were also no differences in HTR3A, HTR3B and CYP2D6 polymorphisms between major depressive disorders and anxiety disorders (P ¼ 0.341).
Effects of HTR3A and HTR3B gene polymorphisms The genotype distribution of HTR3A and HTR3B gene polymorphisms are shown in Tables 1 and 2. No significant  differences were demonstrated The relation between the HTR3 gene and nausea T Sugai et al P ¼ 0.038). The proportion of Ser allele carriers (i.e., patients with either Tyr/Ser or Ser/Ser) was significantly higher in the group without nausea (w 2 ¼ 6.082, df ¼ 1, P ¼ 0.014). There were significant differences in the severity score of nausea among the three genotypes (score: 0.5470.91, 0.1470.49 and 070, df ¼ 2, P ¼ 0.03).
The results of logistic regression analysis are shown in Table 4 . The incidence with or without nausea was used in the analysis as an independent variable, and sex, age, daily dose of paroxetine and the genotypes of HTR3B Tyr129Ser were added as potential confounders. This analysis also showed that there was a significant association between nausea and HTR3B Tyr129Ser genotype. (P ¼ 0.048; OR ¼ 3.95; 95% CI ¼ 1.009-15.455).
Effect of CYP2D6 gene polymorphism
Five CYP2D6 genotypes were identified: *1/*1 (n ¼ 51), *1/*5 (n ¼ 1), *1/*10 (n ¼ 11), *5/*10 (n ¼ 3) and *10/*10 (n ¼ 12). The allele frequencies of the *5 and *10 alleles were 2.6 and 24.4%, respectively. Patients were divided into three genotype groups according to the number of mutated alleles: 51 patients with the *1/*1 genotype, 12 with the *1/*10 and *1/ *5 genotypes and 15 with the *5/*10 and *10/*10 genotypes. No significant differences were demonstrated for sex, age, and paroxetine daily dose and plasma concentration between those three genotype groups (Table 3) .
There were no significant differences in the incidence of nausea between the three genotype groups (w 2 ¼ 1.029, df ¼ 2, P ¼ 0.716). We also divided patients into two genotype groups: 61 patients with the *1/*1 or *1/*10 genotype were termed normal metabolizers, and 17 patients with the *10/*10, *1/*5 or *5/*10 genotype were termed low metabolizers. However, there were also no significant differences in the incidence of nausea between the two genotype groups.
Discussion
We screened for two polymorphisms in the HTR3A gene and one variant in the HTR3B gene as a pharmacodynamic factor, and CYP2D6 gene polymorphisms (*1, *5, *10 alleles) as a pharmacokinetic factor. To our knowledge, the present study is the first demonstration that the HTR3B gene may predict the incidence of paroxetine-induced nausea in Japanese psychiatric patients.
Kaiser et al. 18 reported that polymorphisms of the HTR3A gene may not serve as pharmacogenetic predictors of antiemetic treatment with HTR3 antagonists in cancer The relation between the HTR3 gene and nausea T Sugai et al patients. We also found no relationship between HTR3A gene polymorphism and paroxetine-induced nausea. Tremblay et al. 12 reported that the Tyr129Ser polymorphism of the HTR3B gene did not alter the incidence of nausea and vomiting. However, in the present study, there was a significant relationship between the Tyr129Ser polymorphism of the HTR3B gene and paroxetine-induced nausea. On the other hand, Tremblay et al.
12 also reported that an insertion/deletion polymorphism in the promoter region of the HTR3B gene had a significant effect on the incidence of nausea and vomiting induced by cancer chemotherapy, although we did not examine this insertion/deletion polymorphism. This discrepancy may occur because of the difference in medication, that is, cancer chemotherapy versus paroxetine. We cannot account for this discrepancy between the previous and the present study because the function of the HTR3B gene polymorphism still remains unclear. To date, there are no in vitro data about the functional effects of the Tyr129Ser polymorphism in HTR3B gene. With regard to the functional effects of the other polymorphism in HTR3B gene, Cazzola et al. 19 report that a 6-bp deletion in the 5 0 UTR of L-ferritin mRNA is a cause of hereditary hyperferritinanemia-cataract syndrome, and Frank et al. 20 report that the deletion *À100_À102delAAG polymorphism may change the structure of mRNA compared to the wild type. However, the Tyr129Ser polymorphism of HTR3B gene had an amino-acid substitution in the coding region, and it was possible that the Tyr129Ser polymorphism of HTR3B gene affected the expression level of the B subunit either by itself, or because of linkage disequilibrium with other yet unknown functional variants, and this polymorphism of HTR3B gene may affect the occurrence of nausea by itself, or indirectly. Meanwhile, Murphy et al. 10 reported that the T102C polymorphism of the HTR2A gene could predict the treatment discontinuation caused by paroxetine-induced side effects in older patients with depression. In future studies, we should also examine the relationship between HTR2A gene polymorphism and paroxetine-induced nausea.
In our study, the CYP2D6 gene polymorphism had no significant effect on the incidence of paroxetine-induced nausea. Murphy et al. 10 reported that the CYP2D6 genotype did not influence side effects of paroxetine. Gerstenberg et al.
14 also reported that the number of CYP2D6 mutated alleles was not related to the development of fluvoxamineinduced nausea. Our present results support these previous findings.
Kasper et al. 1 reported that there was a relationship between plasma concentration of fluvoxamine and incidence of nausea. Sawamura et al. 21 showed that plasma paroxetine concentration in patients with CYP2D6*10 alleles was significantly higher than those without *10 alleles, and plasma paroxetine concentration in patients with *5 alleles also showed a tendency to be higher than those without *5 alleles. Therefore, we hypothesized that the CYP2D6 gene polymorphism had a significant influence on paroxetine-induced nausea, but it did not affect paroxetineinduced nausea in the present study. Sindrup et al. 22 reported that the effect of CYP2D6 on metabolism was less prominent at steady-state than after a single dose of paroxetine, since CYP2D6 enzymatic activity seems to be easily saturated upon increasing paroxetine dose. This may be one of the reasons that there was no effect on paroxetineinduced nausea. Furthermore, the groups with two mutated alleles were expected to have the highest concentration among these three genotype groups, but the concentration in groups with two mutated alleles was lower than in groups with one mutated allele, and was the same as in groups with no mutated allele ( Table 3 ). This result suggests that there are patients who had noncompliance with paroxetine in the group with *5/*10 and *10/*10 alleles, since they discontinued because of various adverse events other than nausea, as a result of a great increase in plasma paroxetine concentration.
We demonstrated that a pharmacodynamic factor such as the Tyr129Ser polymorphism of the HTR3B gene may be a predictor of paroxetine-induced nausea in Japanese psychiatric patients. Taking account of these findings, in clinical situations, it may be possible to tailor paroxetine pharmacotherapy based on genetic factors. However, since the results of some previous studies are not consistent with our current results, further study is needed to clarify these discrepancies.
